Thirty years of Alzheimer's disease genetics: the implications of systematic meta-analyses
The DOI matches its Crossref record; 113 of the 113 references it cites were found in a registry or an index.
Abstract
The genetic underpinnings of Alzheimer's disease (AD) remain largely elusive despite early successes in identifying three genes that cause early-onset familial AD (those that encode amyloid precursor protein (APP) and the presenilins (PSEN1 and PSEN2)), and one genetic risk factor for late-onset AD (the gene that encodes apolipoprotein E (APOE)). A large number of studies that aimed to help uncover the remaining disease-related loci have been published in recent decades, collectively proposing or refuting the involvement of over 500 different gene candidates. Systematic meta-analyses of these studies currently highlight more than 20 loci that have modest but significant effects on AD risk. This Review discusses the putative pathogenetic roles and common biochemical pathways of some of the most genetically and biologically compelling of these potential AD risk factors.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The ε4 allele of the apolipoprotein E (APOE) gene is the major genetic risk factor for AD and dementia with Lewy bodies (DLB) (1, 5, 6), whereas APOE2, a well-established longevity determinant, affords protection against the disease (7, 8).”
From APOE3 -Jacksonville (V236E) variant reduces self-aggregation and risk of dementia (2021) · cites this paper as [1]
In the citing paper
“Familial Alzheimer’s disease, which has an autosomal dominant form of inheritance and early onset, has been associated with mutations in APP, PSEN1 and PSEN2, three genes that are critical for beta amyloid (Aβ) production61.”
From Dendritic spine pathology in neuropsychiatric disorders (2011) · cites this paper as [61]
Citations
Cites
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552
Goate, A., Chartier-Harlin, M.-C., Mullan, M., Brown, J., Crawford, F., Fidani, L., Giuffra, L., Haynes, A., Irving, N., James, L., et al. (1991) · Nature · doi:10.1038/349704a0 · Cited by 4,659
Strittmatter, W. J., Saunders, A. M., Schmechel, D., Pericak-Vance, M., Enghild, J., Salvesen, G. S., & Roses, A. D. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.5.1977 · Cited by 4,268
Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease
Sherrington, R., Rogaev, E. I., Liang, Y., Rogaeva, E. A., Levesque, G., Ikeda, M., Chi, H., Lin, C., Li, G., Holman, K., et al. (1995) · Nature · doi:10.1038/375754a0 · Cited by 4,051
Self-citationAssociation of apolipoprotein E allele ϵ4 with late‐onset familial and sporadic Alzheimer's disease
Saunders, A. M., Strittmatter, W. J., Schmechel, D., St. George-Hyslop, P. H., Pericak-Vance, M. A., Joo, S. H., Rosi, B. L., Gusella, J. F., Crapper-MacLachlan, D. R., Alberts, M. J., et al. (1993) · Neurology · doi:10.1212/wnl.43.8.1467 · Cited by 3,786
Genome-wide association studies for complex traits: consensus, uncertainty and challenges
McCarthy, M. I., Abecasis, G. R., Cardon, L. R., Goldstein, D. B., Little, J., Ioannidis, J. P. A., & Hirschhorn, J. N. (2008) · Nature Reviews Genetics · doi:10.1038/nrg2344 · Cited by 2,891
Candidate gene for the chromosome 1 familial Alzheimer’s disease locus
Levy-Lahad, E., Wasco, W., Poorkaj, P., Romano, D. M., Oshima, J., Pettingell, W. H., Yu, C.-E., Jondro, P. D., Schmidt, S. D., Wang, K., et al. (1995) · Science · doi:10.1126/science.7638622 · Cited by 2,577
Self-citationTau-mediated neurodegeneration in Alzheimer’s disease and related disorders
Ballatore, C., Lee, V. M.-Y., & Trojanowski, J. Q. (2007) · Nature Reviews Neuroscience · doi:10.1038/nrn2194 · Cited by 2,174 · cited 1×
“Despite the lack of MAPT mutations in AD, it is likely that tau dysfunction still contributes to AD ris”
BackgroundRogaev, E. I., Sherrington, R., Rogaeva, E. A., Levesque, G., Ikeda, M., Liang, Y., Chi, H., Lin, C., Holman, K., Tsuda, T., et al. (1995) · Nature · doi:10.1038/376775a0 · Cited by 2,052
Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database
Bertram, L., McQueen, M. B., Mullin, K., Blacker, D., & Tanzi, R. E. (2007) · Nature Genetics · doi:10.1038/ng1934 · Cited by 1,857 · cited 1×
“, none of these candidates has been proved to consistently influence disease risk or onset age in more than a handful of sample”
BackgroundSelf-citation
Research works printed but not linked: 1
- Meyer, J. M. & Breitner, J. C. Multiple threshold model for the onset of Alzheimer's disease in the NAS-NRC twin panel. Am. J. Med. Genet. 81, 92–97 (1998). · DOI · Paper page
Cited by
Items 201–300 of 754
Zetzsche, T., Rujescu, D., Hardy, J., & Hampel, H. (2010) · Expert Review of Molecular Diagnostics · doi:10.1586/erm.10.48 · Cited by 60
Tran, T. T., Srivareerat, M., & Alkadhi, K. A. (2010) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.12.016 · Cited by 60
“While numerous articles have been published on various genetic factors of AD, insufficient attention has been directed at the influence of chronic stress on the severity and time of onset of the disease in AD patients (Tanzi and Bertram, 2005; Bertram and Tanzi, 2008).”
BackgroundRamsden, H. L., Sürmeli, G., McDonagh, S. G., & Nolan, M. F. (2015) · PLOS Computational Biology · doi:10.1371/journal.pcbi.1004032 · Cited by 58
Beta-Amyloid and Tau-Protein: Structure, Interaction, and Prion-Like Properties
Tatarnikova, O. G., Орлов, М. А., & Bobkova, N. V. (2015) · Biochemistry (Moscow) · doi:10.1134/s000629791513012x · Cited by 69
Vega, J. N., Hohman, T. J., Pryweller, J. R., Dykens, E. M., & Thornton-Wells, T. A. (2015) · Brain Connectivity · doi:10.1089/brain.2014.0266 · Cited by 58
Sabb, F. W., Burggren, A. C., Higier, R. G., Fox, J., He, J., Parker, D. S., Poldrack, R. A., Chu, W., Cannon, T. D., Freimer, N. B., et al. (2009) · Neuroscience · doi:10.1016/j.neuroscience.2009.05.013 · Cited by 58
“The apolipoprotein E gene and associated protein are involved in the breakdown of beta-amyloid deposits and has been implicated in Alzheimer’s disease (Bertram and Tanzi, 2008).”
BackgroundHenderson, S. T., & Poirier, J. (2011) · BMC Medical Genetics · doi:10.1186/1471-2350-12-137 · Cited by 58
Implication of CLU gene polymorphisms in Chinese patients with Alzheimer's disease
Yu, J., Li, L., Zhu, Q.-X., Zhang, Q., Zhang, W., Wu, Z., Guan, J., & Tan, L. (2010) · Clinica Chimica Acta · doi:10.1016/j.cca.2010.06.013 · Cited by 65
Shi, H., Belbin, O., Medway, C., Brown, K., Kalsheker, N., Carrasquillo, M., Proitsi, P., Powell, J., Lovestone, S., Goate, A., et al. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2012.02.014 · Cited by 57
“…i a f t w n u c ( h s l w F q G C m w D A s i s N U M o B b I C L H g M U a S Q D U M M c I O L multaneously, and a very stringent significance threshold (p 5 10 8) is often used to infer a genome-wide significant association and to avoid a large number of false positives (Bertram and Tanzi, 2008).”
BackgroundReynolds, C. A., Hong, M.-G., Eriksson, U. K., Blennow, K., Wiklund, F., Johansson, B., Malmberg, B., Berg, S., Alexeyenko, A., Grönberg, H., et al. (2010) · Human Molecular Genetics · doi:10.1093/hmg/ddq079 · Cited by 57
“From single candidate gene studies (15), to pathway approaches (16), to genome-wide association (17), no additional genes with as convincing statistical support have emerged.”
BackgroundSawamura, S., Shirakawa, H., Nakagawa, T., Mori, Y., & Kaneko, S. (2017) · CRC Press eBooks · doi:10.4324/9781315152837-16 · Cited by 68
Lambert, J.-C., Sleegers, K., González-Pérez, A., Ingelsson, M., Beecham, G. W., Hiltunen, M., Combarros, O., Bullido, M. J., Brouwers, N., Bettens, K., et al. (2010) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-100933 · Cited by 56
“While these observations highlight the importance of genetic factors in the risk for developing AD, at present, only the ε4 allele of the apolipoprotein E (APOE) gene has been unequivocally identified as a major determinant for the non-Mendelian forms of AD [4–6].”
BackgroundSelf-citationZhang, C., Browne, A., Child, D., DiVito, J. R., Stevenson, J. A., & Tanzi, R. E. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.079079 · Cited by 56
Self-citationRecent insights into the roles of circular RNAs in human brain development and neurologic diseases
Najafi, S., Zarch, S. M. A., Majidpoor, J., Pordel, S., Aghamiri, S., Rasul, M. F., Asemani, Y., Vakili, O., Mohammadi, V., Movahedpour, A., et al. (2022) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2022.11.166 · Cited by 57
Targeting tumor invasion: the roles of MDA-9/Syntenin
Kegelman, T., Das, S. K., Emdad, L., Hu, B., Menezes, M. E., Bhoopathi, P., Wang, X.-Y., Pellecchia, M., Sarkar, D., & Fisher, P. (2014) · Expert opinion on therapeutic targets · doi:10.1517/14728222.2014.959495 · Cited by 54
“Synaptic function is tightly regulated, and dysfunction can be associated with a variety of neurological pathology, including neurodegenerative states such as Alzheimer’s, and psychiatric disorders such as schizophrenia [41].”
Backgroundda Costa, I. M., de Moura Freire, M. A., de Paiva Cavalcanti, J. R. L., de Araújo, D. P., Norrara, B., Moreira Rosa, I. M. M., de Azevedo, E. P., do Rego, A. C. M., Filho, I. A., & Guzen, F. P. (2019) · Current Neuropharmacology · doi:10.2174/0929867325666180117112610 · Cited by 55
Effects of ApoE4 and maternal history of dementia on hippocampal atrophy
Andrawis, J. P., Hwang, K. S., Green, A. E., Kotlerman, J., Elashoff, D., Morra, J. H., Cummings, J. L., Toga, A. W., Thompson, P. M., & Apostolova, L. G. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.07.020 · Cited by 54
Allele-specific RNAi Mitigates Phenotypic Progression in a Transgenic Model of Alzheimer's Disease
Rodríguez-Lebrón, E., Gouvion, C. M., Moore, S. A., Davidson, B. L., & Paulson, H. L. (2009) · Molecular Therapy · doi:10.1038/mt.2009.123 · Cited by 58
Amyloid beta receptors responsible for neurotoxicity and cellular defects in Alzheimer’s disease
Kam, T., Gwon, Y., & Jung, Y. (2014) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-014-1706-0 · Cited by 64
“Mutations in APP and presenilin (PS), a catalytic unit of c-secretase, elicit familial AD by driving the amyloidogenic pathway [3].”
BackgroundSilva, D., Chioua, M., Samadi, A., Agostinho, P. M., Garção, P., Lajarín-Cuesta, R., Ríos, C. D. L., Iriepa, I., Moraleda, I., González‐Lafuente, L., et al. (2013) · ACS Chemical Neuroscience · doi:10.1021/cn300178k · Cited by 58
Amyloid Precursor Protein Translation Is Regulated by a 3’UTR Guanine Quadruplex
Crenshaw, E. M. D., Leung, B. C. L., Kwok, C. K., Sharoni, M. A., Olson, K. J., Sebastian, N. P., Ansaloni, S., Schweitzer‐Stenner, R., Akins, M. R., Bevilacqua, P. C., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0143160 · Cited by 63
Long-term episodic memory decline is associated with olfactory deficits only in carriers of ApoE-є4
Olofsson, J., Josefsson, M., Ekström, I., Wilson, D. A., Nyberg, L. H., Nordin, S., Adolfsson, A. N., Adolfsson, R., Nilsson, L., & Larsson, M. U. (2016) · Neuropsychologia · doi:10.1016/j.neuropsychologia.2016.03.004 · Cited by 60
Yildirimer, L., Zhang, Q., Kuang, S., Cheung, C.-W. J., Chu, K. A., He, Y., Yang, M., & Zhao, X. (2019) · Biofabrication · doi:10.1088/1758-5090/ab17aa · Cited by 53
Milind, N., Preuss, C., Haber, A., Ananda, G., Mukherjee, S., John, C., Shapley, S., Logsdon, B. A., Crane, P. K., & Carter, G. W. (2020) · PLOS Genetics · doi:10.1371/journal.pgen.1008775 · Cited by 53
“GWAS for LOAD have identified variants in over 500 genes as potential risk factors with the ε4 variant in APOE as the strongest contributor to overall disease risk [2,5].”
BackgroundAmyloid-β Production Via Cleavage of Amyloid-β Protein Precursor is Modulated by Cell Density
Zhang, C. M., Browne, A., DiVito, J. R., Stevenson, J. A., Romano, D., Dong, Y., Xie, Z., & Tanzi, R. E. (2010) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-100816 · Cited by 60
“Importantly,the increase of A β 42 :A β 40 ratio has been identified in more than 200 FAD mutations in A β PP , PSEN1 , and PSEN2 , which drivethe aggregation of A β into neurotoxic oligomeric assemblies [1,2].”
InfluentialSelf-citationRole of Medium Chain Triglycerides (Axona®) in the Treatment of Mild to Moderate Alzheimer’s Disease
Sharma, A., Bemis, M., & Desilets, A. R. (2014) · American Journal of Alzheimer's Disease & Other Dementias® · doi:10.1177/1533317513518650 · Cited by 52
The Interaction Between NF-κB and Estrogen in Alzheimer’s Disease
Mishra, P., Davies, D. A., & Albensi, B. C. (2023) · Molecular Neurobiology · doi:10.1007/s12035-022-03152-3 · Cited by 51
Okonkwo, O. C., Alosco, M. L., Jerskey, B. A., Sweet, L. H., Ott, B. R., Tremont, G. N., & Initiative, A. D. N. (2010) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2010.02.003 · Cited by 54
“Possible explanations include its role in amyloid aggregation, fibrillization, and clearance [40], in neurofibrillary tangle formation [41], in regulation of the brain’s vasculature [42], in the metabolism of lipids [40], and in the modulation of other risk factors [43].”
Neurodegenerative diseases: exercising towards neurogenesis and neuroregeneration
Ang, E. (2010) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2010.00025 · Cited by 55
“Some genes (APP, PSEN1, PSEN2, ApoE) (Bertram and Tanzi, 2008; Sando et al., 2008), related cholesterol and inflammatory factors have also been extensively investigated (Beffert et al.”
Influence of ADAM10 on prion protein processing and scrapie infectiosity in vivo
Endres, K., Mitteregger, G., Kojro, E., Kretzschmar, H. A., & Fahrenholz, F. (2009) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.07.015 · Cited by 59
APP heterozygosity averts memory deficit in knockin mice expressing the Danish dementia BRI2 mutant
Tamayev, R., Matsuda, S., Giliberto, L., Arancio, O., & D'adamio, L. (2011) · The EMBO Journal · doi:10.1038/emboj.2011.161 · Cited by 54
“…as Presenilins and BRI2, cause dementias (Goate et al, 1990; Fotinopoulou et al, 2005; Matsuda et al, 2005, 2009; St George-Hyslop and Petit, 2005; Bertram and Tanzi, 2008; Garringer et al, 2009), emphasizes the relevance of APP processing to AD patho- genesis and prompted us to postulate that…”
BackgroundMa, C., Su, J., Sun, Y., Feng, Y., Shen, N., Li, B., Liang, Y., Yang, X., Wu, H., Zhang, H., et al. (2019) · Angewandte Chemie International Edition · doi:10.1002/anie.201912399 · Cited by 51
Self-citationNon-apolipoprotein E and apolipoprotein E genetics of sporadic Alzheimer's disease
Seripa, D., Panza, F., Franceschi, M., D’Onofrio, G., Solfrizzi, V., Dallapiccola, B., & Pilotto, A. (2009) · Ageing Research Reviews · doi:10.1016/j.arr.2008.12.003 · Cited by 52
Olfactory copy number association with age at onset of Alzheimer disease
Shaw, C. A., Li, Y., Wiszniewska, J., Chasse, S., Zaidi, S., Jin, W., Dawson, B., Wilhelmsen, K. C., Lupski, J. R., Belmont, J. W., et al. (2011) · Neurology · doi:10.1212/wnl.0b013e3182166df5 · Cited by 51
Kwon, S.-H., Ma, S., Hong, S., Kim, S. Y., Lee, S., & Jang, C. (2014) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2013.12.048 · Cited by 49
Family history of Alzheimer disease predicts hippocampal atrophy in healthy middle-aged adults
Okonkwo, O. C., Xu, G., Dowling, N. M., Bendlin, B. B., LaRue, A., Hermann, B. P., Koscik, R., Jonaitis, E., Rowley, H. A., Carlsson, C. M., et al. (2012) · Neurology · doi:10.1212/wnl.0b013e3182583047 · Cited by 49
Choi, D.-H., Kwon, K.-C., Hwang, D.-J., Koo, J., Um, H.-S., Song, H., Kim, J., Jang, Y., & Cho, J. (2021) · Molecular Neurobiology · doi:10.1007/s12035-021-02335-8 · Cited by 52
Sivananthan, S. N., Lee, A. W., Goodyer, C. G., & LeBlanc, A. C. (2010) · Cell Death & Disease · doi:10.1038/cddis.2010.74 · Cited by 48
“Familial AD occurs either via APP duplication or single point mutations of the amyloid precursor protein (APP) and Presenilin genes.(5,6) No studies have reported the effect of familial AD-associated mutant proteins on Casp6 activity.”
BackgroundThe potential applications of Apolipoprotein E in personalized medicine
Villeneuve, S., Brisson, D., Marchant, N. L., & Gaudet, D. (2014) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2014.00154 · Cited by 48
“…risk factor for late onset Alzheimer Disease (AD) (Poirier et al., 1993; Leduc et al., 2011; Verghese et al., 2011) with ApoE4 carriers having a 4 to 12-fold increased risk of developing AD when compared to non-carriers (Corder et al., 1993, 1994; Bertram and Tanzi, 2008; Mahley and Huang, 2012a).”
BackgroundCaberlotto, L., Lauria, M., Nguyen, T.-P., & Scotti, M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0078919 · Cited by 49
“AD is the most prevalent 44 neurodegenerative disorder worldwide and it is a complex disease associated with multiple genes 45 [2].”
BackgroundThe contribution of astrocytes to Alzheimer's disease
Birch, A. M. (2014) · Biochemical Society Transactions · doi:10.1042/bst20140171 · Cited by 47
Beeler, N., Riederer, B. M., Waeber, G., & Abderrahmani, A. (2009) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2009.07.006 · Cited by 52
Cognitive health begins at conception: addressing dementia as a lifelong and preventable condition
Barnett, J. H., Hachinski, V., & Blackwell, A. D. (2013) · BMC Medicine · doi:10.1186/1741-7015-11-246 · Cited by 49
“Late-onset AD and VaD are both moderately heritable and although most individual genes increase risk by only a small amount, the apoliprotein E (APOE) ε4 allele confers a threefold to four fold increase in risk for AD [13] and a more modest increase in VaD [14].”
BackgroundWang, X., Zhang, X., Zhou, T.-T., Li, N., Jang, C.-Y., Xiao, Z., Ma, Q., & Li, S. (2016) · Frontiers in Neuroscience · doi:10.3389/fnins.2016.00094 · Cited by 49
“Aβ1−42 Increases Excitability in Cultured Cortical Neurons from Mice It is likely that diverse factors contribute to the pathogenesis of AD patients or mice (Blennow et al., 2006; Bertram and Tanzi, 2008; Mucke, 2009).”
BackgroundJosefsson, M., Larsson, M. U., Nordin, S., Adolfsson, R., & Olofsson, J. (2017) · Scientific Reports · doi:10.1038/s41598-017-01508-7 · Cited by 49
The Role of Reelin Signaling in Alzheimer’s Disease
Yu, N., Tan, M., Yu, J., Xie, A., & Tan, L. (2015) · Molecular Neurobiology · doi:10.1007/s12035-015-9459-9 · Cited by 51
Bales, K. R. (2012) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2012.666234 · Cited by 45
“In aggregate, there are now well more than 100 gene mutations, the majority of which are located in PS1, which are associated with FAD [19].”
BackgroundInfluentialCerebral Amyloid Angiopathy, Blood-Brain Barrier Disruption and Amyloid Accumulation in SAMP8 Mice
del Valle, J., Duran-Vilaregut, J., Manich, G., Pallàs, M., Camins, A., Vilaplana, J., & Pelegrí, C. (2011) · Neurodegenerative Diseases · doi:10.1159/000324757 · Cited by 45
“susceptibility to late-onset AD shows no apparent familial aggregation [”
BackgroundDarawi, M. N., Ai-Vyrn, C., Ramasamy, K., Hua, P. P. J., Pin, T. M., Kamaruzzaman, S. B., & Majeed, A. B. A. (2013) · BMC Medical Genetics · doi:10.1186/1471-2350-14-27 · Cited by 47
What can imaging tell us about cognitive impairment and dementia?
Narayanan, L., & Murray, A. D. (2016) · World Journal of Radiology · doi:10.4329/wjr.v8.i3.240 · Cited by 48
Amyloid–β peptides time-dependent structural modifications: AFM and voltammetric characterization
Enache, T. A., Paquim, A.-M. C., & Oliveira‐Brett, A. M. (2016) · Analytica Chimica Acta · doi:10.1016/j.aca.2016.04.015 · Cited by 46
Recent Advances in Multi-target Anti-Alzheimer Disease Compounds (2013 Up to the Present)
Wang, N., Qiu, P., Cui, W., Yan, X., Zhang, B., & He, S. (2018) · Current Medicinal Chemistry · doi:10.2174/0929867326666181203124102 · Cited by 49
Intermediate Phenotypes Identify Divergent Pathways to Alzheimer's Disease
Shulman, J. M., Chibnik, L. B., Aubin, C., Schneider, J. A., Bennett, D. A., & De Jager, P. L. (2010) · PLoS ONE · doi:10.1371/journal.pone.0011244 · Cited by 44
“Thirty-two candidate SNPs were selected based on their discovery in AD GWA studies and/or evidence from the AlzGene online meta-analyses [2,26].”
MethodZhang, H., Rombouts, K., Raes, L., Xiong, R., Smedt, S. C. D., Braeckmans, K., & Remaut, K. (2020) · Advanced Biosystems · doi:10.1002/adbi.202000057 · Cited by 45
Bertram, L., & Tanzi, R. E. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2009.213 · Cited by 48
Self-citationPresenilin mouse and zebrafish models for dementia: Focus on neurogenesis
van Tijn, P., Kamphuis, W., Marlatt, M. W., Hol, E. M., & Lucassen, P. J. (2010) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2010.10.008 · Cited by 44
“…numerous extra- and intracellular deposits of misprocessed, misfolded and aberrant proteins are found, such as amyloid-b (Ab), hyperphosphorylated tau and ubiquitinated proteins, which accumulate during the course of the disease (Bertram and Tanzi, 2008; Hol et al., 2005; LaFerla et al., 2007).”
BackgroundLiu, Y., Xu, L., Wang, S., Yang, W., Wen, Y., & Zhang, X. (2015) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2015.04.068 · Cited by 46
“…and Sensing g, Beijing 100083, PR China. of APOE4 allele were three to four times more likely to suffer from developing AD than those without APOE4 allele, and APOE4 homozygosity allele increased the risk more than tenfold (Corder et al., 1993; Bertram and Tanzi, 2008; Roses and Saunders, 1994).”
BackgroundLee, A. Y., Lee, M. H., Lee, S., & Cho, E. J. (2017) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.7b03941 · Cited by 50
Alichniewicz, K., Brunner, F., Klünemann, H. H., & Greenlee, M. W. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2012.02.010 · Cited by 49
TRP Channels: New Potential Therapeutic Approaches in CNS Neuropathies
Morelli, M. B., Amantini, C., Liberati, S., Santoni, M., & Nabissi, M. (2013) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/18715273113129990056 · Cited by 46
“In fact about 5% of AD cases are familial and characterized by mutations and duplications in genes important for amyloid -peptide (A ) production: presenilins 1 and 2 and amyloid precursor protein (APP) [215].”
BackgroundSynergistic associations of depression and apolipoprotein E genotype with incidence of dementia
Kim, J., Stewart, R., Kim, S., Kim, S., Bae, K., Yang, S., Shin, I., & Yoon, J. (2011) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.2621 · Cited by 42
Genetic association of PICALM polymorphisms with Alzheimer's disease in Han Chinese
Yu, J., Song, J., Ma, T., Zhang, W., Yu, N., Xuan, S., & Tan, L. (2010) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2010.09.027 · Cited by 44
“Aiming to identify new Alzheimer's disease loci, several genome-wide association studies (GWAS) have been previously conducted [2].”
BackgroundInfluentialMethodology for Discovery of Alzheimer's Disease Blood-Based Biomarkers
Maes, O. C., Schipper, H. M., Chertkow, H. M., & Wang, E. (2009) · The Journals of Gerontology Series A · doi:10.1093/gerona/glp045 · Cited by 45
Panza, F., Seripa, D., Lozupone, M., Solfrizzi, V., Imbimbo, B. P., Barulli, M. R., Tortelli, R., Capozzo, R., Bisceglia, P., Dimitri, A., et al. (2018) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2018.1389885 · Cited by 41
Neurotechnological Approaches to the Diagnosis and Treatment of Alzheimer’s Disease
Ning, S., Jorfi, M., Patel, S. R., Kim, D. Y., & Tanzi, R. E. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.854992 · Cited by 48
Self-citationRoles of Calcium Stores and Store-Operated Channels in Plasticity of Dendritic Spines
Segal, M., & Korkotian, E. (2015) · The Neuroscientist · doi:10.1177/1073858415613277 · Cited by 43
Seo, J.-S., Yun, J.-H., Baek, I., Leem, Y.-H., Kang, H.-W., Cho, H. K., Lyu, Y.-S., Son, H.-J., & Han, P. (2010) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2010.01.014 · Cited by 42
Muresan, V., & Muresan, Z. (2009) · Future Neurology · doi:10.2217/fnl.09.54 · Cited by 41
“However, the association of SORL1 (the gene encoding SORLA) with LOAD is still debated [7].”
BackgroundInfluentialKaushik, R., Morkovin, E. I., Schneeberg, J., Confettura, A. D., Kreutz, M. R., Senkov, O., & Dityatev, A. E. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00411 · Cited by 39
“In particular, aging is a major determinant of the onset, progression, and pathogenesis of the most common form of dementia, Alzheimer’s disease (AD; Lindsay et al., 2002; Bertram and Tanzi, 2008).”
BackgroundNuclear Receptors, Inflammation, and Neurodegenerative Diseases
Saijo, K., Crotti, A., & Glass, C. K. (2010) · Advances in immunology · doi:10.1016/s0065-2776(10)06002-5 · Cited by 43
Mielke, M. M., Leoutsakos, J.-M., Tschanz, J. T., Green, R. C., Tripodis, Y., Corcoran, C. D., Norton, M. C., & Lyketsos, C. G. (2011) · Journal of Alzheimer's Disease · doi:10.3233/jad-2011-110086 · Cited by 40
“3–times more likely to develop AD, while the risk for homozygous carriers is even higher [2, 3].”
Sugarman, M. A., Woodard, J. L., Nielson, K. A., Seidenberg, M., Smith, J. C., Durgerian, S., & Rao, S. M. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2011.09.016 · Cited by 44
“Two well-established risk factors for late-onset, nonsporadic AD are a history of dementia in a first-degree relative [12] and possession of one or more apolipoprotein (APOE) ε4 alleles [13–15].”
Hamilton, L. K., & Fernandes, K. J. L. (2017) · Biology of the Cell · doi:10.1111/boc.201700037 · Cited by 43
“For example, the principal genetic risk factor for sporadic AD is polymorphism at the ApoE gene [Bertram and Tanzi, 2008], which encodes a major lipid-carrying apolipoprotein of the brain.”
BackgroundAlzheimer’s Genetics in the GWAS Era: A Continuing Story of ‘Replications and Refutations’
Bertram, L. (2011) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-011-0193-z · Cited by 43
Self-citationDrug pipeline in neurodegeneration based on transgenic mice models of Alzheimer's disease
Li, C., Ebrahimi, A., & Schluesener, H. J. (2012) · Ageing Research Reviews · doi:10.1016/j.arr.2012.09.002 · Cited by 50
Zhang, D., Fan, Y., Wang, D., Bi, R., Zhang, C., Fang, Y., & Yao, Y. (2015) · Molecular Neurobiology · doi:10.1007/s12035-015-9353-5 · Cited by 50
Kwon, S., Hong, S., Jung, Y., Kim, M., Kim, S. Y., Kim, H., Lee, S., & Jang, C. (2011) · Food and Chemical Toxicology · doi:10.1016/j.fct.2011.12.026 · Cited by 41
“…diseases such as PD, Alzheimer’s disease (AD), stroke, and depression are mainly caused by oxidative damage, many plants have demonstrated efficacy in both in vivo and in vitro models (Bertram and Tanzi, 2008; Driscoll and Gerstbrein, 2003; Mayo et al., 2005; Moreira et al., 2010).”
BackgroundHereditary and Sporadic Forms of Aβ-Cerebrovascular Amyloidosis and Relevant Transgenic Mouse Models
Kumar-Singh, S. (2009) · International Journal of Molecular Sciences · doi:10.3390/ijms10041872 · Cited by 38
Increased Glutaminyl Cyclase Expression in Peripheral Blood of Alzheimer's Disease Patients
Valenti, M. T., Bolognin, S., Zanatta, C., Donatelli, L., Innamorati, G., Pampanin, M., Zanusso, G., Zatta, P. F., & Carbonare, L. D. (2013) · Journal of Alzheimer s Disease · doi:10.3233/jad-120517 · Cited by 38
Jin, C., Li, W., Yuan, J., Xu, W., & Cheng, Z. (2012) · Neuroscience Letters · doi:10.1016/j.neulet.2012.08.032 · Cited by 39
Elucidating the Molecular Determinants of Aβ Aggregation with Deep Mutational Scanning
Gray, V. E., Sitko, K., Kameni, F. Z. N., Williamson, M., Stephany, J. J., Hasle, N., & Fowler, D. M. (2019) · G3 Genes|Genomes|Genetics · doi:10.1534/g3.119.400535 · Cited by 38
“…and epidemiological work suggests that aggregation of the amyloid β (Aβ) peptide is related to the incurable neurodegeneration associated with Alzheimer’s disease (Hardy and Selkoe 2002; Lesné et al. 2008; Bertram and Tanzi 2008; Shankar et al. 2009; Masters and Selkoe 2012; Hardy 2017).”
Animal Models for Alzheimer’s Disease and Frontotemporal Dementia: A Perspective
Götz, J., & Götz, N. N. (2009) · ASN Neuro · doi:10.1042/an20090042 · Cited by 38
“In addition to the three FAD genes, a series of susceptibility genes have been identified in SAD (sporadic AD); these include APOE (apolipoprotein E) as the most established risk gene (Bertram and Tanzi, 2008).”
BackgroundInfluentialGenetics and epigenetics of Alzheimer's disease
Alagiakrishnan, K., Gill, S. S., & Fagarasanu, A. D. (2012) · Postgraduate Medical Journal · doi:10.1136/postgradmedj-2011-130363 · Cited by 43
“2.(40) Among these lower risk susceptible genes, the ones coding for sortilin-related receptor (SORL1),(41) death-associated protein kinase 1,(42) ubiquilin 1(43) and ATPbinding cassette transporter I, subfamily A(44) on chromosome 9, and low-density lipoprotein receptor related protein 6 on chromosome 12,(45) are all…”
BackgroundNing, M., Yang, Y., Zhang, Z., Chen, Z., Zhao, T., Zhang, D., Zhou, D., Xu, J., Liu, Z., Wang, Y., et al. (2010) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0b013e3181e6a575 · Cited by 37
Alzheimer’s disease: diagnostics, prognostics and the road to prevention
Grossman, I., Lutz, M. W., Crenshaw, D. G., Saunders, A. M., Burns, D. K., & Roses, A. D. (2010) · EPMA Journal · doi:10.1007/s13167-010-0024-3 · Cited by 37
Varamini, B., Sikalidis, A. K., & Bradford, K. L. (2014) · International Journal of Food Sciences and Nutrition · doi:10.3109/09637486.2013.832171 · Cited by 37
Neurotransmitter Pathway Genes in Cognitive Decline During Aging: Evidence for GNG4 and KCNQ2 Genes
Bonham, L. W., Evans, D. S., Liu, Y., Cummings, S. R., Yaffe, K. S., & Yokoyama, J. S. (2018) · American Journal of Alzheimer s Disease & Other Dementias® · doi:10.1177/1533317517739384 · Cited by 38
“Although recent research has broadened our understanding of the genetic underpinnings of cognitive decline and dementia, much remains to be understood.(8,9) Evidence from studies in humans and rodents suggests that neurotransmitter function declines in aging and that these changes could be associated with risk of deme…”
BackgroundIncreased Alu RNA processing in Alzheimer brains is linked to gene expression changes
Cheng, Y., Saville, L., Gollen, B., Alvarez-Veronesi, A., Mohajerani, M. H., Joseph, J. T., & Zovoilis, A. (2021) · EMBO Reports · doi:10.15252/embr.202052255 · Cited by 38
“…trials for potential therapeutic factors in AD remain inconclusive, as AD remains a highly complex disease, with extreme heterogeneity and many of the molecular processes underlying its pathogenesis still elusive (Bertram & Tanzi, 2008; Korczyn, 2012; Toledo et al , 2013; Hane et al , 2017).”
Samadi, A., Revenga, M. D. L. F., Pérez, C., Iriepa, I., Moraleda, I., Rodríguez-Franco, M. I., & Marco, J. L. (2013) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2013.06.021 · Cited by 40
Evaluation of annexin A5 as a biomarker for Alzheimer's disease and dementia with lewy bodies
Sohma, H., Imai, S.-I., Takei, N., Honda, H., Matsumoto, K., Utsumi, K., Matsuki, K., Hashimoto, E., Saito, T., & Kokai, Y. (2013) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2013.00015 · Cited by 36
“The ε4 allele of the ApoE gene was identified as the strongest genetic risk factor for AD (Bertram and Tanzi, 2008).”
BackgroundGenetics of Alzheimer's Disease
Bertram, L., & Tanzi, R. E. (2011) · Wiley eBooks · doi:10.1002/9781444341256.ch9 · Cited by 41
Self-citationLysosomal Calcium in Neurodegeneration
Feng, X., & Yang, J. (2016) · Messenger · doi:10.1166/msr.2016.1055 · Cited by 41
“PS1 and PS2 are key components of γ-secretase, a protein complex resides on plasma membrane that cleaves APP to amyloid-β (Aβ peptides (Bertram and Tanzi 2008).”
BackgroundCousins, K. A. Q., Phillips, J. S., Irwin, D. J., Lee, E. B., Wolk, D. A., Shaw, L. M., Zetterberg, H., Blennow, K., Burke, S. E., Kinney, N. G., et al. (2021) · Alzheimer's & Dementia · doi:10.1002/alz.12233 · Cited by 38
Torres, M., Matamala, J. M., Duran-Aniotz, C. A., Cornejo, V. H., Foley, A., & Hetz, C. A. (2014) · Virus Research · doi:10.1016/j.virusres.2014.12.018 · Cited by 43
“Mutations in three genes have been linked to the development of rare familial and early onset forms of AD (Bertram and Tanzi, 2008).”
BackgroundThe search for neuroimaging biomarkers of Alzheimer's disease with advanced MRI techniques
Li, T., & Wahlund, L. (2011) · Acta Radiologica · doi:10.1258/ar.2010.100053 · Cited by 37
Desforges, N. M., Hebron, M., Algarzae, N. K., Lonskaya, I., & Moussa, C. (2012) · International Journal of Alzheimer's Disease · doi:10.1155/2012/345472 · Cited by 43
“The causal association between mutations in APP and the onset of familial AD supports the role of Aβ in AD pathogenesis [65].”
BackgroundAlzheimer's disease‐causing proline substitutions lead to presenilin 1 aggregation and malfunction
Ben‐Gedalya, T., Moll, L., Bejerano‐Sagie, M., Frère, S. G. A., Cabral, W. A., Friedmann‐Morvinski, D., Slutsky, I., Burstyn‐Cohen, T., Marini, J. C., & Cohen, E. (2015) · The EMBO Journal · doi:10.15252/embj.201592042 · Cited by 38
“Mutations in PS1, a multi-spanning transmembranal aspartic protease which possesses the proteolytic activity of the c -secretase complex (De Strooper et al , 1998), are accountable for the majority of familial AD cases (Bertram & Tanzi, 2008).”
Rossini, P. M., Cappa, S. F., Lattanzio, F., Perani, D., Spadin, P., Tagliavini, F., & Vanacore, N. (2019) · Journal of Alzheimer's Disease · doi:10.3233/jad-190670 · Cited by 35
“Although the total number of AD risk genes remains elusive, there are significant evidences suggesting that their combinations may have a substantial impact on disease susceptibility, time of onset [81], and progression of sporadic late-onset AD.”
Paz‐y‐Miño, C., García-Cárdenas, J. M., López‐Cortés, A., Salazar, C., Leone, P., & Serrano‐Dueñas, M. (2015) · The American Journal of the Medical Sciences · doi:10.1097/maj.0000000000000555 · Cited by 34
“However, early-onset familial AD presents dominant and fully penetrant forms that are caused by variations in 3 genes; amyloid precursor protein (APP), presenilin 1 (PSEN1) and presenilin 2 (PSEN2).(12,13) Early-onset AD is considered rare because it is only present in 5% of all cases.”
BackgroundBorroni, B., Alberici, A., Grassi, M., Rozzini, L., Turla, M., Zanetti, O., Bianchetti, A., Gilberti, N., Bonvicini, C., Volta, G. D., et al. (2011) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0b013e3182147f80 · Cited by 35
“be/AD Mutations/).(4) FTLD affects the frontal and temporal lobes, causing social dysfunctions, personality changes along with cognitive impairment in language and executive functions; mutations in microtubule-associated protein tau (MAPT) or progranulin (PGRN) genes account for a significant proportion of FTLD presen…”
Background
Metadata
- Authors
- Bertram, L., & Tanzi, R. E.
- Affiliations
- Harvard University (US)
- Massachusetts General Hospital (US)
- Corresponding author
- Bertram, Lars
- Venue
- Nature Reviews Neuroscience
- Published
- 2008-10
- Volume
- 9
- Issue
- 10
- Pages
- 768-778
- ISSN
- 1471-003X (ISSN-L)
- 1471-0048
- OpenAlex
- W2018342879
- Cited by
- 747
- References
- 113
- Citations by year
- 2026: 12 · 2025: 16 · 2024: 25 · 2023: 21 · 2022: 33 · 2021: 26 · 2020: 29 · 2019: 34 · 2018: 41 · 2017: 46 · 2016: 37 · 2015: 41 · 2014: 46 · 2013: 59 · 2012: 62
- FWCI
- 7.89
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature reviews. Neuroscience (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health
- National Institute on Aging (5R01-AG23667, R01AG023667)
- National Institute of Mental Health (5R37MH60009, R37MH060009)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Keywords
- Alzheimer's disease genetics, genetic risk factors, candidate genes, meta-analysis, amyloid precursor protein, presenilin 1, presenilin 2, apolipoprotein E, early-onset familial Alzheimer's disease, late-onset Alzheimer's disease, disease pathology, metabolic pathways
- MeSH terms
- Alzheimer Disease, Animals, Apolipoproteins E, Brain Chemistry, Humans, Mutation, Risk Factors, Meta-Analysis as Topic, Amyloid beta-Protein Precursor, Genetic Predisposition to Disease, Presenilins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.